PVC tubing and related medical components require a stabilizer system that supports controlled processing, clear appearance and evaluation under the intended sterilization conditions.
Flexible medical-grade PVC formulations combine PVC resin with plasticizers, lubricants and other additives. Their balance influences fusion, thermal stability, transparency, odor and the finished surface of tubing and molded components.
A suitable PVC stabilizer for medical tubingshould therefore be evaluated as part of the complete formulation. Selection should consider the processing method, required clarity, contact-surface condition, sterilization route and the applicable documentation required by the buyer.
The stabilizer should work with the resin, plasticizer and lubricant system to support consistent fusion and processing. Plate-out, precipitation and surface deposits should be checked under the buyer’s actual production conditions.
Transparent medical tubing and hose require evaluation of initial color, haze, odor and appearance after processing. These results depend on the complete formulation rather than the stabilizer alone.
For ETO or gamma stable PVC tubing, buyers should compare color change, transparency, surface condition and other required properties before and after sterilization. Final suitability must be confirmed through application-specific testing.
Compare three product options for flexible medical tubing, dry-blended medical PVC compounds and transparent hose or related medical components.
A paste-form stabilizer option for manufacturers evaluating flexible medical-grade PVC tubing, including infusion, respiratory or drainage-tubing formulations where paste handling matches the existing compounding process.
A powder-form option for compounders producing PVC tubing and related medical components through dry blending. Selection should consider powder feeding, dispersion and compatibility with the resin, plasticizer and lubricant system.
A paste-form product listed for transparent hose, film and related PVC medical devices. It provides an initial option for tubing and components where transparency, dispersibility and consistent visual appearance are important.
Review the application direction, material form and starting dosage range before arranging formulation and line trials.
| Product | Initial Application Direction | Selection Focus | Form and Packing | Dosage (PHR) |
|---|---|---|---|---|
| AIMSTA-6111 | Flexible medical tubing and soft PVC components | Paste handling, formulation compatibility and application-specific testing | Paste 50 kg/barrel | 2–4 |
| AIMSTA-6809 | Dry-blended medical PVC compounds and tubing materials | Powder dosing, dry blending, dispersion and processing compatibility | Powder 25 kg/bag | 1–2 |
| AIMSTA-6122 | Transparent hose, film and related medical components | Transparency, dispersibility and visual appearance | Paste 50 kg/barrel | 2–4 |
Recommended dosage is a starting reference and should be confirmed according to the complete formulation, intended medical application, sterilization method and actual production conditions.
Share your tubing or component type, PVC resin, plasticizer system, production process, sterilization method and required technical documents. AIMSEA can discuss a suitable product direction for controlled evaluation.
Product selection should begin with the finished medical component and its production requirements, then move to the complete formulation, sterilization route and required technical documentation.
Identify whether the project involves infusion tubing, respiratory tubing, drainage lines, transparent hose, flexible masks, connectors or another soft PVC component. The component type determines which properties should receive priority during product screening.
Clarify whether the finished component will use ETO, gamma irradiation or another validated sterilization method. For gamma stable PVC tubing, the complete formulation should be checked for post-sterilization color, transparency, surface condition and required physical properties.
PVC resin, K value, plasticizer type and phr, lubricants, pigments and other additives can change the behavior of the stabilizer. Paste and powder products should also be matched to the manufacturer’s dosing, mixing and compounding process.
Regulatory and technical requirements vary by finished device, contact type and destination market. Buyers should request the documents available for the selected model and confirm that their scope matches the intended application instead of relying on a general “medical grade” description.
Use the finished application to determine which information and trial checks should be prioritized before approval.
| Application | Initial Selection Priority | Information to Confirm | Evaluation Focus |
|---|---|---|---|
| IV and infusion tubing | Clear fluid-path visibility and clean surface condition | Formulation, contact requirements and sterilization route | Initial color, haze, deposits and post-sterilization appearance |
| Respiratory and oxygen tubing | Low odor, flexibility and consistent tube appearance | Plasticizer system, tube dimensions and sterilization method | Odor, surface condition, color and formulation compatibility |
| Drainage and catheter-related tubing | Smooth surface, dimensional consistency and visibility | Extrusion conditions, formulation and finished-device requirements | Surface quality, deposits, color and processing consistency |
| Transparent hose and flexible components | Transparency, dispersibility and visual consistency | Thickness, clarity target, pigment use and processing method | Haze, initial color, dispersion and surface appearance |
Important:Stabilizer selection alone does not establish the compliance or biocompatibility of a finished medical device. Final suitability should be confirmed using the complete PVC formulation, finished component, intended sterilization process and applicable market requirements.
A controlled evaluation process helps determine whether the selected stabilizer works with the complete formulation, production conditions, sterilization route and finished-component requirements.
Specify whether the product is infusion tubing, respiratory tubing, drainage tubing, transparent hose, a flexible mask component or another PVC medical device.
Share the PVC resin and K value, plasticizer type and phr, lubricant system, pigments, fillers and the stabilizer currently used in production.
Begin with an agreed reference dosage and compare the candidate under equivalent mixing, extrusion or molding conditions rather than changing several formulation variables at once.
Evaluate the processed component before and after the intended sterilization procedure, then confirm the required technical and market documentation separately.
Provide enough detail to narrow the initial product and trial direction.
Record the same evaluation points for the current and candidate formulation.
Fusion, flow, pressure stability, deposits and production consistency.
Initial color, visible haze and clarity of the finished component.
Plate-out, precipitation, surface deposits and visual cleanliness.
Compare odor under the same processing and storage conditions.
Review color, clarity and surface condition after the intended process.
Complete the buyer’s required physical, chemical and regulatory checks.
Trial control:The dosage ranges shown on this page are starting references. Adjustments should be made in controlled steps because the PVC resin, plasticizer, lubricant balance, processing conditions and sterilization method can all affect the result. Finished-device compliance cannot be established from the stabilizer alone.
Submit your application, formulation, production process, sterilization method and current issue to discuss a suitable sample and evaluation direction.
Purchasing questions about medical-grade claims, sterilization, product forms, dosage references and technical documentation.
No. A stabilizer is one component of the complete PVC formulation. Finished-device suitability depends on the resin, plasticizer, lubricant system, pigments, processing conditions, contact type, sterilization process and applicable market requirements. The finished component must be evaluated and documented by the device manufacturer.
No. The performance of gamma stable PVC tubingis influenced by the complete formulation, irradiation dose, exposure conditions, product thickness and acceptable post-sterilization color. Buyers should test the finished tubing before and after irradiation using their intended sterilization conditions.
The choice should reflect the manufacturer’s material-handling and compounding process. Paste products may suit systems designed for liquid or paste dosing, while powder products may suit dry-blending operations. Dispersion, feeding accuracy, compatibility, production cleanliness and finished-product results should be compared during the trial.
The listed phr range is an initial reference, not a fixed production setting. The appropriate dosage can change with the PVC resin, K value, plasticizer level, lubricant balance, pigments, processing temperature and sterilization method. Final dosage should be confirmed through controlled trials.
Buyers can ask for the available TDS, SDS, COA format and model-specific compliance documents. The document scope, issuing organization, test conditions and applicable product should be checked carefully. A general reference to FDA or medical-grade use should not be treated as approval of the finished medical device.
Provide the finished component, PVC resin and K value, plasticizer system, stabilizer currently used, processing method, sterilization route, target appearance and current production issue. This information helps narrow the initial sample direction and prevents unrelated products from being tested.
Share your tubing or component type, formulation, sterilization method and required documents to request a suitable product direction and sample for controlled evaluation.
